ultomiris
Generic: ravulizumab-cwvz·Code: ALXN1210
ultomiris: developed by 1 company · 1 clinical trial tracked.
ultomiris evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ultomiris to ALXN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ultomiris → ALXN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Ultomiris-exposed Pregnant/ PostpartumGeneralized Myasthenia Gravis (gMG)Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ALEXION PHARMACEUTICALS, INC. (ALXN) Ultomiris-exposed Pregnant/ Postpartum | Phase 4 |
Clinical Trials (1)
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Primary endpoint: Pregnancy Complications
Observational75 targetStarted 2024-12Completion 2034-077 sites · Australia, France, Germany, Italy…Alexion Pharmaceuticals, Inc.
Frequently asked questions
Who is developing ultomiris?
ultomiris is being developed by ALEXION PHARMACEUTICALS, INC..
How many clinical trials involve ultomiris?
BioSniper tracks 1 clinical trial involving ultomiris.